{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 29,
  "pageCount": 109,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "pain_points",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process-like icon header to indicate the regulatory stage.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/29",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-29",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Our research highlighted three key challenges in the regulatory stage for innovative medicines",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-ba8c-7422-853c-499aa5f918f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.14,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a936e404-dd2e-4c08-a441-02573cba7783",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.44
      },
      "kind": "list",
      "text": "Misaligned perception of risk / benefit: Different perception of risk and benefit balance across different stakeholder groups; for example very high unmet need patient groups are willing to adopt earlier, but current systems are unable to take these scenarios into account",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10ce238d-f0a8-4dc6-887b-4db20897a213",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "list",
      "text": "Lack of early dialogue: Selective uptake by Industry of available advice on protocol and trial design and low update of HTA early dialogue: for SMEs price is a concern; big pharma feel they already have sufficient in-house capability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6286cd05-1e26-4d14-be27-30476775051b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "Limited access to early approval: Although becoming more common, conditional regulatory approval on limited (Phase I / Phase II) clinical data sets based on continued demonstration of safety and efficacy is restricted to certain product types. This reduces the speed of access to regulatory approval",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff03cde8-feea-41f4-b9b2-417e8e7985ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Our research highlighted three key challenges in the regulatory stage for innovative medicines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f54b8f9e-39ae-47d9-99cf-f2a5ba6cd4de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Stakeholder interviews, workshops and Deloitte analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55446b4b-0ac1-4a49-b206-50de2b8a2883",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.55,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Regulation: Key Challenges",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58007a8e-043c-4423-9169-025e838415dc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "dd83125e-7fc6-4e86-a536-9dafcc0c58af",
      "evidence": "list/bullet: Limited access to early approval: Although becoming more common, conditional regulatory approval on limited (Phase I / Phase II) clinical data sets based on continued demonstration of safety and efficacy is",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 109,
      "from": 21,
      "beatId": "4bae8ed9-97e4-4ca8-988f-171e64b0598d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 109,
      "from": 21,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "575c67ea-abbb-4bd3-80bc-943f97973ed4",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 1,
      "objective": "How can the NHS improve access to medical innovations?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}